SPOTLIGHT: Recall cuts Medtronic profits, but not much

Medtronic's quarterly earnings weren't hit as hard as expected by the recall of its Fidelis defibrillator lead; the device maker posted $666 million in earnings on $3.12 billion in revenues. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.